Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to diagnose chronic rhinitis, a common condition that affects many people around the world, including millions in China. Chronic rhinitis can significantly impact daily life, causing problems like difficulty breathing, nasal congestion, and even affecting mental health. The researchers want to improve how we identify the different types of chronic rhinitis, especially since some people have symptoms of allergies despite negative allergy tests. They will use a specific test called the nasal allergen provocation test (NAPT) to see how well it works in diagnosing allergic rhinitis and local allergic rhinitis.

To participate in this trial, you need to be between 18 and 75 years old and either have allergic rhinitis symptoms or be a healthy volunteer without any nasal issues. However, some people may not be eligible, including those with recent severe allergic reactions, active respiratory diseases, or certain other medical conditions. If you join the study, you can expect to undergo the nasal provocation test, which involves applying allergens to your nose to see if it triggers symptoms. The results could help improve how healthcare providers diagnose and treat chronic rhinitis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• AR patients:
• • Aged 18-75 years;
• • patients who visited the Department of Otorhinolaryngology,the First Affiliated Hospital of Nanjing Medical Uncversity and were willing to undergo nasal provocation test; 3.Ptients who are willing to provide specimens for free to promote the study of the diagnostic efficacy of nasal provocation.
• Healthy volunteers:
• • Aged 18-75 years;
• • Did not have any nasal symptoms and tested negative for allergens
• Exclusion Criteria:
• • Acute rhinosinusitis or acute exacerbation of chronic rhinosinusitis; active phase or symptom exacerbation of allergic diseases (e.g., allergic rhinitis, asthma).
• • History of severe allergic reactions (e.g., anaphylaxis).
• • Severe chronic obstructive pulmonary disease (COPD) or severe cardiopulmonary diseases contraindicating epinephrine use.
• • Active phase of other severe systemic diseases (e.g., malignancies, autoimmune diseases).
• • Within 1 week post-vaccination.
• • Pregnancy, lactation, or preconception period.
• • Inability to comply with study procedures (particularly children under 5 years old).
• • Recent nasal surgery (within 2 months), nasal deformities (e.g., choanal atresia, severe nasal septum deviation/perforation), dry/atrophic rhinitis, severe nasal obstruction (e.g., hypertrophic rhinitis, rhinitis medicamentosa), or uncontrolled epistaxis.
• • Current use of anti-allergy medications, including:Intranasal agents: corticosteroids, antihistamines, decongestants, anticholinergics, sodium cromoglicate;Systemic agents: oral antihistamines, oral/injectable corticosteroids.